Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724380 | 0.78 | CYP17A1 (0.46) | CYP17A1CYP1A2CYP3A4CYP2D6CLK4 | |
| SCHEMBL20371563 | 0.72 | PIK3CD (0.46) | CYP17A1 | |
| SCHEMBL15723936 | 0.70 | KDM4E (0.63) | CYP17A1CYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL20466856 | 0.70 | NCOA1 (0.42) | CYP17A1EIF4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18854138 | 0.69 | MAPK9 (0.48) | CYP1A2CYP3A4CYP2D6KDM4ECYP2C19 | |
| SCHEMBL15730877 | 0.69 | CYP17A1 (0.39) | CYP17A1CYP1A2PTGS2PIK3C3 | |
| SCHEMBL15723948 | 0.68 | CYP17A1 (0.39) | CYP17A1EIF4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21899219 | 0.68 | CYP17A1 (0.41) | CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL10284897 | 0.68 | CHRNA7 (0.40) | CYP3A4CLK4ALDH1A1KMT2APTGS2 | |
| SCHEMBL28823621 | 0.68 | MAP4K4 (0.36) | PTGS2PTGS1MAPK10RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CYP17A1 77/4885EIF4E 975/4885CYP1A2 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.